News

Tigermed-Jyton Supports the Approval of Brattea's Innovative RDN System

Tigermed-Jyton Supports the Approval of the World’s First Renal Nerve Mapping Renal Artery Radiofrequency Ablation Product (msRDN)

Tigermed-Jyton Announces Acquisition of NAMSA China and Global Strategic Partnership with NAMSA

BEIJING, CHINA and TOLEDO, US –February 29, 2024—Tigermed-Jyton, a leading medical device CRO in China, and NAMSA, a global leader MedTech Contract Research Organization (CRO) offering global end-to-end development services, today announced Tigermed-Jyton’s acquisition of NAMSA China, as well as the exclusive China region partnership and global collaboration between Tigermed-Jyton and NAMSA.

Exhibition Recap | Tigermed-Jyton at the MEDICA German Medical Exhibition 2023

The 55th MEDICA in Dusseldorf, Germany took place on November 13-16, 2023 at the Dusseldorf Exhibition Center.

Powerful Association between Tigermed-Jyton and Shanghai SAPH Pharma-Tech | The Strategic Cooperation Signing Ceremony between Tigermed-Jyton and Shanghai SAPH Pharma-Tech is Successfully Completed

Powerful Association between Tigermed-Jyton and Shanghai SAPH Pharma-Tech | The ···

Interpretation of Regulations | Hainan Boao Trial Pre-communication to Help Licensed Drugs and Medical Devices Carry out Real-world Study for Product Registration

On April 25, 2023,theCenter for Medical Device Evaluation, NMPA, Hainan Medical ···

Tigermed-Jyton Accelerates Approval of China’s First Full Magnetic Suspension Artificial Heart—New Hope for Patients with Advanced Heart Failure

Recently, NationalMedical Products Administration (NMPA) approved the registrati···

Tigermed-Jyton and Reunion Reached Strategic Cooperation to Jointly Promote R&D of High-Quality Medical Devices

The signing ceremony for strategic cooperation between Shanghai Reunion Biotechnology...